What Cisbio Bioassays does

Cisbio Bioassays is a France-based in vitro diagnostics (IVD) and life sciences reagent manufacturer founded in 1985 and headquartered in Codolet, France. The company operates with a headcount of 51-100 employees and historically served biomedical research and clinical diagnostics markets globally through a B2B, sales-led direct distribution model. Cisbio has been integrated into Revvity's diagnostics portfolio, with its HTRF life sciences platform transferred to Revvity.com while the IVD kits and proprietary monoclonal antibody business continue under the Cisbio brand.

The company's product platform is built on two pillars. First, a catalog of 44 proprietary monoclonal antibodies (mouse and rat) covering oncology, fertility, growth, bone, thyroid, Down's syndrome, iron metabolism, and inflammation biomarkers, sold both as standalone research reagents and as components integrated into IVD kits. Second, finished IVD kits comprising ELISA and RIA assays for clinical use in autoimmunity (21-hydroxylase, acetylcholine receptor, AQP4, VGCC), diabetes (GAD-Ab, IA-2Ab, ZnT8Ab), oncology/neuroendocrine tumors (Chromogranin A via the patented 145-245 epitope targeting), and fibrosis (PIIINP/P3NP). Several kits hold CE marks including EU MDR certification for fibrosis products. Cisbio's most differentiated technical asset is the patented Chromogranin A assay, described as the only assay targeting the 145-245 core epitope of the CgA molecule.

Revenue is generated through one-time sales of IVD kits and monoclonal antibodies to clinical diagnostic laboratories, pharmaceutical companies, and contract research organizations, priced via direct quote requests with no publicly listed pricing and country-specific variations. Customer support is delivered through an in-house scientific team, a technical hotline, online documentation in multiple languages, and a regulatory affairs service. The website emphasizes 30 years of "precision and quality" as a positioning anchor, with a horizontal segmentation approach addressing both clinical diagnostics (primary) and pharmaceutical research/CRO (secondary) use cases.

Name

Cisbio Bioassays

Legal name

Cisbio Bioassays

Website

https://cisbio.net

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

51–100 employees

Short description

Cisbio Bioassays is a France-based IVD manufacturer founded in 1985 that produces CE-marked ELISA and RIA kits plus 44 proprietary monoclonal antibodies for clinical diagnostics, pharmaceutical research, and CRO customers in autoimmunity, diabetes, oncology, and fibrosis applications, now operating within Revvity's portfolio.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Clinical Chemistry & Immunoassay Systems (HLAHAAAA)

akta.pro secondary industries

Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

Keywords

• In vitro diagnostics
• Ivd immunoassays
• Monoclonal antibodies
• Elisa kits
• Clinical diagnostics

Headquarters

HQ city

Codolet

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. IVD Diagnostic Kits Sales: Sale of in vitro diagnostic ELISA and RIA kits for clinical diagnostics including autoimmunity, diabetes, oncology, and fibrosis applications. Products sold as finished kits with established specifications.
2. Monoclonal Antibodies: Sale of proprietary monoclonal antibodies (44 products catalog) for research and IVD kit manufacturing purposes, supplied as purified proteins in PBS.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Cisbio Bioassays manufactures and sells in vitro diagnostic immunoassay kits (ELISA and immunoradiometric assays) for clinical diagnostics in autoimmunity, diabetes, oncology, and fibrosis applications, alongside a proprietary catalog of 44 monoclonal antibodies used as components in IVD kits and for research purposes. Products include CE-marked diagnostic kits with batch-specific certificates of analysis.

Product overview

Cisbio Bioassays provides in vitro diagnostics solutions focused on biological research and diagnostic testing. The company offers two main product lines: (1) a comprehensive portfolio of 44 proprietary monoclonal antibodies used as components in IVD kits and for research purposes, covering biomarkers across oncology, fertility, growth, bone, thyroid, and inflammation categories; and (2) finished in vitro diagnostic ELISA and RIA kits for clinical diagnostics in autoimmune diseases (21-hydroxylase, AChR, AQP4, VGCC antibodies), diabetes (GAD-Ab, IA-2Ab, ZnT8Ab), oncology/neuroendocrine tumors (Chromogranin A), and fibrosis (Procollagen III peptide/P3NP). The HTRF portfolio has been transferred to Revvity, while the in vitro diagnostics and monoclonal antibodies remain under the Cisbio brand. Products feature various assay technologies including sandwich ELISA, competition ELISA, and immunoradiometric assays (RIA).

Differentiator

Problem solved

Functional benefit

Brands

• HTRF: Heterogeneous Time-Resolved Fluorescence technology platform for life sciences research - portfolio moved to Revvity.com
• IVD Kits
• Chromoa

Products and services

• Chromogranin A ELISA kit (Chromoa R) The only patented assay targeting the core of the molecule (145-245) to measure intact and fragmented Chromogranin A (CgA). Used for diagnosis, evaluation of treatment efficiency, and prognostic factor for neuroendocrine tumors (NETs), pheochromocytoma, gastrinoma, carcinoid tumors, and as an adverse prognostic factor in prostate cancer.
• Chromogranin A ELISA-NG kit New generation version of the patented Chromogranin A assay targeting the core of the molecule (145-245) to measure intact and fragmented CgA. Designed to follow guidelines for diagnosis and treatment follow-up for neuroendocrine tumors (NETs).
• Procollagen-III-peptide (PIIINP) ELISA kit (CE) CE-marked sandwich ELISA assay for determination of human procollagen III peptide in blood to monitor fibroses, reducing the number of necessary patient biopsies. Detects liver fibrosis, cirrhosis, psoriatic patients treated by MTX, NAFLD, lung fibrosis, chronic polyarthritis, collagenosis, myocardial infection, acromegaly, and multiple traumas.
• Procollagen-III-peptide (PIIINP) ELISA kit (P3NP-EL-US) One-step colorimetric immunoassay for determination of human procollagen III peptide (P3NP) in blood for fibrosis research. For Research Use Only, not for use in diagnostic procedures.
• Glutamic acid decarboxylase autoantibody (GADAb) ELISA kit Accurate enzymatic assay used to measure GAD-Ab 65 in human serum to differentiate for type I diabetes mellitus. Working range: 5-2000 U/mL with analytical sensitivity of 0.57 U/mL.
• IA2 autoantibody (IA-2Ab) ELISA kit Enzymatic assay to measure Tyrosine phosphatase (IA2-Ab) Islet Antigen autoantibodies in human serum. Important pre-clinical markers of type I diabetes mellitus. Working range: 7.5-4000 U/mL.
• Two Screen islet cell autoantibody (GADAb & IA-2Ab) ELISA kit ELISA test measuring levels of glutamic acid decarboxylase and IA-2 autoantibodies in a single serum sample to identify type I diabetes mellitus. Working range: 4-450 U/mL.
• Zinc transporter 8 autoantibody (ZnT8Ab) ELISA kit Quantitative determination of zinc transporter 8 autoantibodies associated with type I diabetes mellitus. Quantifies ZnT8 autoantibodies specific to R325, W325, or residue 325 non-specific variants. Working range: 10-2000 U/mL.
• 21-hydroxylase autoantibody ELISA kit Accurate enzymatic assay measuring 21-hydroxylase autoantibodies in human serum. Identifies patients with autoimmune Addison's disease and screens for adrenal autoimmune diseases. Working range: 0.3-100 U/mL.
• Acetylcholine Receptor Autoantibody (ACHRAb) ELISA kit Accurate enzymatic assay used to measure acetylcholine receptor autoantibodies in human serum related to myasthenia gravis. Assists in diagnosis of neuromuscular junction failure and monitors disease. Working range: 0.5-20 nmol/L.
• Aquaporin-4 autoantibody (AQP4Ab) ELISA kit Enzymatic assay to measure AQP4 autoantibodies in human serum to identify autoimmune diseases of central nervous system. Diagnoses neuromyelitis optica (NMO/Devic's syndrome) and distinguishes NMOSD from multiple sclerosis. Working range: 1.5-80 U/mL.
• P-Type VGCC Autoantibody immunoradiometric assay kit (VGC/25) Immunoradiometric assay for P-Type Voltage-Gated Calcium Channel autoantibodies to identify channelopathies and neurological disorders such as Lambert-Eaton myasthenic syndrome (LEMS).
• Monoclonal Antibodies Portfolio Portfolio of 44 proprietary monoclonal antibodies for use in IVD kits and research purposes. Includes antibodies for Oncology (19), Fertility (8), Growth (7), Bone (6), Thyroid (6), Down's Syndrome (2), Iron metabolism (2), Other Biomarker (2), Anti-species (1), and Inflammation (1). Antibodies include Anti-hCG, Anti-hGH, Anti-AFP, Anti-CEA, Anti-CRP, Anti-Ferritin, Anti-FSH, Anti-IgG, Anti-LH, Anti-Myoglobin, Anti-Osteocalcin, Anti-PAP, Anti-PAPP-A, Anti-Prolactin, Anti-PSA, Anti-PTH, Anti-T3, Anti-T4, Anti-Thyroglobulin, Anti-TSH.

Quantifiable outcome

• Reduce number of necessary patient biopsies through fibrosis monitoring
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• RevvitycoreStrategic or Co-development PartnerCisbio's leading life sciences and in vitro solutions are now part of Revvity's portfolio. The HTRF portfolio has been moved to Revvity. This represents an acquisition/integration of Cisbio's product lines under Revvity's diagnostics business.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• QuidelOrtho: Diversified IVD company across immunoassay, molecular, and rapid diagnostics; competes in clinical lab segments where Cisbio's specialty IVD kits are placed.
• Bio-Rad Laboratories: Diversified life science and clinical diagnostics vendor supplying immunoassay controls, ELISA kits, and specialty IVD reagents to research and clinical labs; an established incumbent in adjacent diagnostic menus.
• DiaSorin: Italy-based global IVD leader with broad specialty immunoassay menu including infectious disease, endocrinology, and autoimmune — competes in the same customer sites with automated LIAISON platforms.

Direct peers

• EKF Diagnostics: UK-based specialty diagnostics company with point-of-care and ELISA offerings in fertility, hCG, and metabolic biomarkers — overlapping Cisbio's fertility and oncology/hCG kits.
• ORGENTEC Diagnostika: German specialty IVD maker focused on autoimmune ELISA kits (e.g., rheumatic, infectious, thrombosis serology) — directly comparable to Cisbio's autoimmune autoimmune IVD range.
• DRG International: Specialty IVD manufacturer of ELISA and RIA kits across endocrinology, oncology, and autoimmune biomarkers — closely mirrors Cisbio's specialty autoimmune and hormone diagnostic kit portfolio.
• Monobind Inc: US-based niche IVD maker of ELISA and CLIA kits focused on fertility, thyroid, and specialty biomarkers — directly comparable to Cisbio's therapeutic-area coverage.
• Calbiotech: Specialty ELISA kit manufacturer covering autoimmune, infectious disease, and biomarker assays, with a similar focus on validated manual immunoassay formats and OEM/research supply.
• RSR Ltd: Wales-based specialty developer of ELISA and RIA kits for autoantibody diagnostics, including type 1 diabetes (GADAb, IA-2Ab, ZnT8Ab) — directly overlapping Cisbio's autoimmune and diabetes kits.

Emerging players

• Euroimmun (Revvity): Autoimmune diagnostics leader (now operating within Revvity alongside Cisbio) — directly overlapping focus on autoantibody ELISA/IIFT, creating intra-portfolio peer dynamics post-acquisition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/CisbioBioassays
• LinkedInlinkedin.com/company/cisbio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cisbio Bioassays